Dexmedetomidine Enhancing the Recovery After Cardiac Surgery

Benha University

Status

Completed

Conditions

Post-cardiac Surgery

Treatments

Drug: Fentanyl

Drug: Lidocain

Drug: Dexmedetomidine

Study type

Interventional

Funder types

Other

Identifiers

NCT06907277

RC 17-11-2024

Details and patient eligibility

About

Enhanced Recovery After Surgery (ERAS) aims to facilitate a quicker and smoother recovery period following surgical procedures. The implementation of these protocols may lead to patients returning to their daily activities sooner, experiencing greater satisfaction with their care, and potentially encountering fewer complications, ultimately contributing to shorter hospital stays. However, a common challenge in the postoperative phase is postoperative delirium(POD). This complication can lead to both immediate and long-term cognitive impairments, negatively impact overall health outcomes, and increase the financial burden on the healthcare system. Interestingly, dexmedetomidine, known as DXM, is a medication that selectively targets certain receptors in the brain and offers sedative properties with minimal impact on breathing. This characteristic is noteworthy because it may help regulate sleep patterns and support the preservation of cognitive function during the recovery period.

Enrollment

75 patients

Sex

All

Ages

40 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients of American Society of Anesthesiologists Classification (ASA) grade II-III;
Patients who were planned to have Coronary Artery Bypass Graft (CABG);
Patients were free of exclusion criteria.

Exclusion criteria

Patients with preoperative high risk for getting Post Operative Delirium or sleep disorders,
Patients with American Society of Anesthesiologists Classification (ASA) grade>III;
Patients with heart failure, left ventricle ejection fraction of <25%,
Patients with uncontrolled diabetes mellitus, coagulopathy, or history of uncompensated renal or hepatic diseases